Non-Small Cell Lung Cancer

Phase III SMART trial of Xcytrin begins

Published in Cancer Weekly, January 21st, 2003

Pharmacyclics, Inc., (PCYC) announced that it has begun its pivotal phase III trial of Xcytrin (motexafin gadolinium) Injection for the potential treatment of lung cancer patients with brain metastases (i.e., lung cancer that has spread to the brain from another part of the body).

This randomized, controlled study, known as the SMART (study of neurologic progression with motexafin gadolinium and radiation therapy) trial, is designed to enroll 550 patients at over 100 leading medical centers in the United States, Canada, Europe, and Australia. It will compare the effects of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin. The primary efficacy endpoint...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry